Please use this identifier to cite or link to this item:Volltext verfügbar? / Dokumentlieferung
|Title:||Quantity, quality, and functionality of peripheral blood cells derived from residual blood of different apheresis kits|
Friedmann, Kim S.
Schwarz, Eva C.
|Title:||Transfusion : the journal of the American Association of Blood Banks|
|Year of Publication:||2018|
|Publikation type:||Journal Article|
|Abstract:||BACKGROUND Research with primary human white blood cell (WBC) subpopulations requires high quantity, quality, and functionality of peripheral blood mononuclear cells (PBMCs) as a source to further characterize cellular subpopulations such as T and B lymphocytes, monocytes, or natural killer cells. Apart from buffy coats derived from whole blood, residual blood from preparative hemapheresis kits are used as a source for PBMCs, but knowledge on the yield and functionality of cells from different devices is limited. STUDY DESIGN AND METHODS We evaluated quantity and quality of PBMCs isolated from apheresis kits of two apheresis devices (AMICUS, Fenwal; and Trima Accel, Terumo BCT), the latter being our standard source for many years. PBMCs derived from Trima or AMICUS were tested for yield and subtype composition by flow cytometry. Functionality was assessed by cytokine induction of CD4⁺ and CD8⁺ T cells and by degranulation. Moreover, cytotoxic activity of natural killer cells was quantified by a real‐time killing assay. RESULTS Mean numbers of isolated cells were 5.5 ± 2.4 × 10⁸ for AMICUS, and 10.3 ± 6.4 × 10⁸ for Trima Accel, respectively. The proportion of WBC subtypes corresponded to well‐known numbers from whole blood, with minor differences between the two apheresis systems. Likewise, minor differences in cytokine induction were found in stimulated CD4⁺ or CD8⁺ T cells. Finally, PBMCs derived from the two systems showed comparable cytotoxic activity. CONCLUSION PBMC derived from residual blood of the AMICUS and Trima Accel apheresis devices serve as an economic and easily accessible source for functional PBMCs with comparable quantity and quality to PBMCs derived from whole blood.|
|DOI of the first publication:||10.1111/trf.14616|
|URL of the first publication:||https://onlinelibrary.wiley.com/doi/abs/10.1111/trf.14616|
|Link to this record:||hdl:20.500.11880/27654|
|Date of registration:||10-Aug-2019|
|Faculty:||M - Medizinische Fakultät|
|Department:||M - Infektionsmedizin|
|Professorship:||M - Prof. Dr. Martina Sester|
Files for this record:
There are no files associated with this item.
Items in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.